In the last trading session, 0.29 million Inozyme Pharma Inc (NASDAQ:INZY) shares changed hands as the company’s beta touched 1.34. With the company’s per share price at $2.93 changed hands at -$0.08 or -2.66% during last session, the market valuation stood at $188.22M. INZY’s last price was a discount, traded about -166.21% off its 52-week high of $7.80. The share price had its 52-week low at $2.38, which suggests the last value was 18.77% up since then. When we look at Inozyme Pharma Inc’s average trading volume, we note the 10-day average is 0.79 million shares, with the 3-month average coming to 476.91K.
Analysts gave the Inozyme Pharma Inc (INZY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.10. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended INZY as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Inozyme Pharma Inc’s EPS for the current quarter is expected to be -0.38.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Inozyme Pharma Inc (NASDAQ:INZY) trade information
Instantly INZY was in red as seen at the end of in last trading. With action -0.34%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -31.22%, with the 5-day performance at -0.34% in the red. However, in the 30-day time frame, Inozyme Pharma Inc (NASDAQ:INZY) is 4.27% up. Looking at the short shares, we see there were 3.41 million shares sold at short interest cover period of 7.59 days.
The consensus price target for the stock as assigned by Wall Street analysts is 16, meaning bulls need an upside of 81.69% from its current market value. According to analyst projections, INZY’s forecast low is 16 with 16 as the target high. To hit the forecast high, the stock’s price needs a -446.08% plunge from its current level, while the stock would need to soar -446.08% for it to hit the projected low.
Inozyme Pharma Inc (INZY) estimates and forecasts
Data shows that the Inozyme Pharma Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -33.71% over the past 6 months, a -16.79% in annual growth rate that is considerably lower than the industry average of 16.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -35.73%. The 2024 estimates are for Inozyme Pharma Inc earnings to decrease by -16.72%, but the outlook for the next 5-year period is at 13.10% per year.
INZY Dividends
Inozyme Pharma Inc is expected to release its next quarterly earnings report in January.
Inozyme Pharma Inc (NASDAQ:INZY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.51% of Inozyme Pharma Inc shares while 98.53% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 99.03%. There are 98.53% institutions holding the Inozyme Pharma Inc stock share, with ADAGE CAPITAL PARTNERS GP, L.L.C. the top institutional holder. As of 2024-06-30, the company held 9.2742% of the shares, roughly 5.73 million INZY shares worth $25.55 million.
PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC holds the second largest percentage of outstanding shares, with 7.2765% or 4.49 million shares worth $20.05 million as of 2024-06-30.
